Innate Pharma has started a new program named IPH43, to develop an anti-MICA therapeutic antibody in oncology. The program is the newest to emerge from the company's discovery platform. MICA, which is highly polymorphic ligand of the NK ...
Tags: Innate Pharma, Anti-Mica Antibody